The Role of Neuromuscular Blockade in Acute Respiratory Distress Syndrome

Steven Pass, PharmD, FCCM, BCPS
Associate Professor and
Vice Chair for Residency Programs

Learning Objectives

- Identify the subset of Acute Respiratory Distress Syndrome (ARDS) patients who may benefit from neuromuscular blockade
- Discuss complications related to neuromuscular blockade

Neuromuscular blocking agents (NMBA)

- Non-depolarizing
  - Competitively antagonize acetylcholine receptors
  - Bind to the receptor and do not allow depolarization to occur
- Examples:
  - Vecuronium
  - Rocuronium
  - Cisatracurium

When to use?

SCCM / ASHP Clinical Practice Guidelines

NMBA should be used to manage ventilation only when all other means have been tried without success:

- Optimal sedation?
- Maximal sedation?
- Sedation that makes us comfortable?

Practical approach

- Pressure control with PIP > 50 cm water
  - I time > 1.5 sec
  - SaO₂ < 90% on > 50% FiO₂
- PaO₂ / FiO₂ < 150
- Ventilator dyssynchrony
  - PIP > 50 cm water
  - Spontaneous respiratory rate > 30

University of Cincinnati Hospital, 1994.

NMBAs in early ARDS

- Multicenter, double-blind trial
- Onset of ARDS within 48 hours
- Inclusion criteria:
  - PaO₂/ FiO₂ less than 150
  - PEEP of 5 cm water
  - Tidal volume 6-8 mL/kg
  - Bilateral infiltrates consistent with edema
- 339 patients randomized to 48 hours of:
  - Cisatracurium - set rate of 37.5 mg/hr
  - Placebo

**NMBAs in early ARDS**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Cisatracurium</th>
<th>Placebo</th>
<th>RR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>28 day mortality</td>
<td>42/177 (23.7%)</td>
<td>54/182 (30.3%)</td>
<td>0.71 (0.51-0.91)</td>
<td>0.05</td>
</tr>
<tr>
<td>Vaso-free days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1 – 10</td>
<td>10.6 ± 8.7</td>
<td>8.5 ± 9.4</td>
<td>1.03 (0.98-1.09)</td>
<td>0.04</td>
</tr>
<tr>
<td>Day 1 – 30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days outside the ICU</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1 – 26</td>
<td>6.0 ± 6.2</td>
<td>5.7 ± 5.6</td>
<td>1.06 (0.90-1.25)</td>
<td>0.05</td>
</tr>
<tr>
<td>Vaso-free days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trauma</td>
<td>9/177 (5.1%)</td>
<td>18/162 (11.1%)</td>
<td>0.43 (0.2-0.89)</td>
<td>0.03</td>
</tr>
</tbody>
</table>


**NMBAs in early ARDS**

- NMBAs beneficial:
  - Higher probability of survival higher in the group with a PaO2/FiO2 less than 120
  - Higher probability of breathing without assistance at 90 days


**Meta-analysis - Survival**

![Survival Analysis](image)


**Meta-analysis – Adverse events**

![Adverse Events Analysis](image)


**NMBAs Complications**

- Prolonged recovery
- Nerve compression
- Venous thromboembolism
- Pressure ulcers
- Corneal ulcerations
- Cardiovascular
  - Tachycardia
  - Hypotension
Prolonged ICU weakness

- Pre-existing conditions
- Steroid myopathy
- Hyperglycemia
- Acute myopathy of critical illness
- Critical illness polyneuropathy
- Disuse atrophy

NMBA related weakness

- Prolonged recovery from NMBA
  - Drug / metabolite accumulation
- Acute Quadriplegic Myopathy Syndrome
  - Acute paresis
  - Myonecrosis
  - Abnormal electromyogram
  - Reduced compound motor action potential

Prevention of NMBA related weakness

- Intermittent administration
- Lower dosages
- Minimize exposure
  - Drug holidays
- Clinical monitoring
  - Train of four

Learning Assessment Question

Which of the following subsets of patients with ARDS may benefit from neuromuscular blockade?

a. Refractory hypoxemia
b. Ventilator dyssynchrony
c. Increased work of breathing
d. All of the above

Conclusion

- Utilization of neuromuscular blockade may be beneficial in ARDS patients
  - Early therapy (<48 hours of onset)
  - PaO₂ / FiO₂ < 120
  - Ventilator dyssynchrony
- Factors to consider:
  - Adequate sedation and pain control
  - Optimize ventilator settings
  - Minimize total time and dosage of NMBA
  - Clinical monitoring